Detalhe da pesquisa
1.
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Drug Metab Dispos
; 52(7): 690-702, 2024 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719744
2.
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir.
Xenobiotica
; 53(1): 12-24, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803165
3.
Intersystem Extrapolation Factors Are Substrate-Dependent for CYP3A4: Impact on Cytochrome P450 Reaction Phenotyping.
Drug Metab Dispos
; 50(3): 249-257, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903590
4.
An improved method for cytochrome p450 reaction phenotyping using a sequential qualitative-then-quantitative approach.
Drug Metab Dispos
; 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777845
5.
Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach.
Drug Metab Dispos
; 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777846
6.
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Drug Metab Dispos
; 50(5): 576-590, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35153195
7.
Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5'-Diphosphate-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity.
Drug Metab Dispos
; 46(6): 805-812, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29581103
8.
Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.
Drug Metab Dispos
; 45(10): 1102-1112, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28768682
9.
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
J Med Chem
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687966
10.
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Science
; 374(6575): 1586-1593, 2021 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726479